Genmab Statistics

Total Valuation

Genmab has a market cap or net worth of GBP 9.24 billion. The enterprise value is 6.78 billion.

Market Cap	9.24B
Enterprise Value	6.78B

Important Dates

The next estimated earnings date is Thursday, August 7, 2025.

Earnings Date	Aug 7, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	61.50M
Shares Outstanding	n/a
Shares Change (YoY)	-61.77%
Shares Change (QoQ)	+587.81%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	60.81M

Valuation Ratios

The trailing PE ratio is 10.48 and the forward PE ratio is 12.26.

PE Ratio	10.48
Forward PE	12.26
PS Ratio	3.70
PB Ratio	2.26
P/TBV Ratio	3.75
P/FCF Ratio	10.31
P/OCF Ratio	10.00
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.31, with an EV/FCF ratio of 7.56.

EV / Earnings	7.69
EV / Sales	2.63
EV / EBITDA	7.31
EV / EBIT	7.73
EV / FCF	7.56

Financial Position

The company has a current ratio of 5.34, with a Debt / Equity ratio of 0.03.

Current Ratio	5.34
Quick Ratio	5.32
Debt / Equity	0.03
Debt / EBITDA	0.12
Debt / FCF	0.12
Interest Coverage	59.70

Financial Efficiency

Return on equity (ROE) is 22.80% and return on invested capital (ROIC) is 13.34%.

Return on Equity (ROE)	22.80%
Return on Assets (ROA)	11.54%
Return on Invested Capital (ROIC)	13.34%
Return on Capital Employed (ROCE)	18.83%
Revenue Per Employee	947,948
Profits Per Employee	334,335
Employee Count	2,682
Asset Turnover	0.54
Inventory Turnover	11.54

Taxes

In the past 12 months, Genmab has paid 141.84 million in taxes.

Income Tax	141.84M
Effective Tax Rate	13.85%

Stock Price Statistics

The stock price has decreased by -23.83% in the last 52 weeks. The beta is 0.82, so Genmab's price volatility has been lower than the market average.

Beta (5Y)	0.82
52-Week Price Change	-23.83%
50-Day Moving Average	1,368.33
200-Day Moving Average	1,471.91
Relative Strength Index (RSI)	32.92
Average Volume (20 Days)	10,037

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Genmab had revenue of GBP 2.50 billion and earned 881.97 million in profits. Earnings per share was 14.21.

Revenue	2.50B
Gross Profit	2.38B
Operating Income	849.59M
Pretax Income	1.02B
Net Income	881.97M
EBITDA	886.02M
EBIT	849.59M
Earnings Per Share (EPS)	14.21

Full Income Statement

Balance Sheet

The company has 2.50 billion in cash and 110.68 million in debt, giving a net cash position of 2.39 billion.

Cash & Cash Equivalents	2.50B
Total Debt	110.68M
Net Cash	2.39B
Net Cash Per Share	n/a
Equity (Book Value)	4.10B
Book Value Per Share	64.71
Working Capital	2.54B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 924.10 million and capital expenditures -27.16 million, giving a free cash flow of 896.94 million.

Operating Cash Flow	924.10M
Capital Expenditures	-27.16M
Free Cash Flow	896.94M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 95.12%, with operating and profit margins of 33.97% and 35.27%.

Gross Margin	95.12%
Operating Margin	33.97%
Pretax Margin	40.94%
Profit Margin	35.27%
EBITDA Margin	35.43%
EBIT Margin	33.97%
FCF Margin	35.87%

Dividends & Yields

Genmab does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	61.77%
Shareholder Yield	n/a
Earnings Yield	9.54%
FCF Yield	9.70%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Genmab has an Altman Z-Score of 9.65 and a Piotroski F-Score of 5.

Altman Z-Score	9.65
Piotroski F-Score	5